This is a limited company view. Sign up for a Free Trial to see everything.

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

B2B
Biotechnology
Enterprise Software
Healthcare
Pharmaceuticals

Overview

Location

Boston

Founded

2013

Employees

122

Stage

Public

Total funding

$103M

Last funding

3 years ago

Acquisitions

0

Growth score

121

Mindshare score

-2

Scoring

Employee Growth

Use Jounce Therapeutics's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use Jounce Therapeutics's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial

Key People

Chief Executive Officer and President
Director
Director
Director
Abeloff Professor of Oncology, Director, Cancer Immunology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, Director of the Center for Human Immunology and Immunotherapy programs, Washington University School of Medicine
Director, Georgetown Lombardi Comprehensive Cancer Center, Professor and Chair, Department of Oncology, Georgetown University Medical Center
Chairman
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Similar Companies

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is developing a new approach for cancer immunotherapy.
Series B

Gain context with Mattermark Salesforce Enrichment

Find out how

Notes